View ValuationAgilent Technologies 将来の成長Future 基準チェック /26Agilent Technologies利益と収益がそれぞれ年間12%と6.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.1% 13%なると予測されています。主要情報12.0%収益成長率12.96%EPS成長率Life Sciences 収益成長20.1%収益成長率6.3%将来の株主資本利益率22.14%アナリストカバレッジGood最終更新日22 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 14Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal AdenocarcinomaAgilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase-nvhy), Bristol Myers Squibb’s PD-1-targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. PD-L1 IHC 28-8 pharmDx, Code SK005, is an FDA-approved diagnostic aid for detecting PD-L1 expression (Combined Positive Score [CPS] = 1) in these tumor types for patients being considered for treatment with OPDIVO® or OPDIVO QVANTIG®. PD-L1 expression is determined using CPS, which measures PD-L1 staining in tumor and immune cells relative to the total number of viable tumor cells. Gastric and esophageal cancers continue to represent a significant global health burden, with high mortality rates and limited long-term survival for many patients. Esophageal cancer is the 11th most common cancer worldwide with over 510,000 new cases and is the seventh leading cause of cancer mortality, accounting for over 445,000 cancer deaths each year. Patients with esophageal cancer have an overall five-year survival of 22%. Gastric cancer is the fifth most common cancer worldwide with around 968,000 new cases and is also the fifth leading cause of cancer mortality, accounting for approximately 660,000 cancer deaths each year. Patients with gastric cancer have an overall 5-year survival of 38%. PD-1- and PD-L1-targeted immunotherapies, including OPDIVO®, have transformed treatment approaches across multiple cancer types, underscoring the importance of accurate biomarker testing to help identify patients who may benefit from these therapies. PD-L1 IHC 28-8 pharmDx was developed by Agilent in partnership with Bristol Myers Squibb as part of the clinical development program supporting OPDIVO®. Clinical studies CheckMate-648 and CheckMate-649 demonstrated improvements in overall survival and progression-free survival in patients with ESCC, gastric, GEJ, and esophageal adenocarcinoma treated with OPDIVO® and OPDIVO QVANTIG®. PD-L1 IHC 28-8 pharmDx is manufactured by Agilent Technologies, Inc.お知らせ • Jul 08Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic AnalysisAgilent Technologies Inc. announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production. The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity. By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, Agilent Technologies Inc. is expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows. Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities. For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities. The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows. Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally.お知らせ • Jul 01Agilent Technologies Launches Xcelligence RTCA Esight AI ModuleAgilent Technologies Inc. announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions. Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis. By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise. The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research. By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.お知らせ • Jun 26Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP.Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for approximately $950 million on March 9, 2026. A cash consideration of $950 million will be paid by Agilent Technologies, Inc. As part of consideration, $950 million is paid towards common equity of Biocare Medical, LLC. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group. For the period ending December 31, 2025, Biocare Medical, LLC reported total revenue of $90 million. The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent’s EPS approximately 12 months following close. Barclays Capital Inc. acted as financial advisor for Agilent Technologies, Inc. Sullivan & Cromwell LLP acted as legal advisor for Agilent Technologies, Inc. Joele Frank is serving as strategic communications adviser to Agilent. Jefferies LLC acted as financial advisor for Biocare Medical, LLC. Ropes & Gray LLP acted as legal advisor for Biocare Medical, LLC. Barclays Bank PLC acted as financial advisor for Agilent Technologies, Inc. ICR Healthcare is serving as strategic communications adviser to Biocare. Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP on June 25, 2026. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).Recent Insider Transactions • Jun 06Independent Director recently sold €186k worth of stockOn the 29th of May, G. Dolsten sold around 2k shares on-market at roughly €116 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €922k more than they bought in the last 12 months.業績と収益の成長予測XTRA:AG8 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数10/31/20288,4071,8471,7522,2451410/31/20277,9011,6351,5912,0822010/31/20267,4481,4661,1571,597204/30/20267,2321,4141,0871,452N/A1/31/20267,0651,2909931,396N/A10/31/20256,9481,3031,1521,559N/A7/31/20256,7881,2201,0881,495N/A4/30/20256,6281,1661,1891,585N/A1/31/20256,5331,2591,3121,697N/A10/31/20246,5101,2891,3731,751N/A7/31/20246,4971,4131,4171,786N/A4/30/20246,5911,2421,5381,896N/A1/31/20246,7351,2361,6491,961N/A10/31/20236,8331,2401,4741,772N/A7/31/20236,9941,1331,4201,704N/A4/30/20237,0401,3511,1831,468N/A1/31/20236,9301,3231,0611,353N/A10/31/20226,8481,2541,0211,312N/A7/31/20226,6591,3281,0221,305N/A4/30/20226,5271,2631,0581,313N/A1/31/20226,4451,2051,2801,502N/A10/31/20216,3191,2101,2971,485N/A7/31/20216,1429901,2681,421N/A4/30/20215,8179251,2531,377N/A1/31/20215,5308101,0921,218N/A10/31/20205,339719802921N/A7/31/20205,223691736858N/A4/30/20205,236683665810N/A1/31/20205,236764N/A749N/A10/31/20195,1631,071N/A1,021N/A7/31/20195,0901,072N/A1,079N/A4/30/20195,0191,117N/A1,034N/A1/31/20194,9871,140N/A1,085N/A10/31/20184,914316N/A1,087N/A7/31/20184,809298N/A1,003N/A4/30/20184,720237N/A1,034N/A1/31/20184,616196N/A988N/A10/31/20174,472684N/A889N/A7/31/20174,394633N/A835N/A4/30/20174,324582N/A801N/A1/31/20174,241509N/A798N/A10/31/20164,202462N/A793N/A7/31/20164,126476N/A800N/A4/30/20164,096465N/A714N/A1/31/20164,040466N/A643N/A10/31/20154,038438N/A1,322N/A7/31/20154,046306N/A1,245N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AG8の予測収益成長率 (年間12% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: AG8の収益 ( 12% ) German市場 ( 15.8% ) よりも低い成長が予測されています。高成長収益: AG8の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: AG8の収益 ( 6.3% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: AG8の収益 ( 6.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AG8の 自己資本利益率 は、3年後には高くなると予測されています ( 22.1 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/27 14:42終値2026/07/24 00:00収益2026/04/30年間収益2025/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Agilent Technologies, Inc. 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関Catherine Ramsey SchulteBairdRobert BambergerBairdCharles ButlerBarclays32 その他のアナリストを表示
お知らせ • Jul 14Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal AdenocarcinomaAgilent Technologies Inc. has received U.S. Food and Drug Administration (FDA) approval for the PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase-nvhy), Bristol Myers Squibb’s PD-1-targeted immunotherapeutic agents. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. PD-L1 IHC 28-8 pharmDx, Code SK005, is an FDA-approved diagnostic aid for detecting PD-L1 expression (Combined Positive Score [CPS] = 1) in these tumor types for patients being considered for treatment with OPDIVO® or OPDIVO QVANTIG®. PD-L1 expression is determined using CPS, which measures PD-L1 staining in tumor and immune cells relative to the total number of viable tumor cells. Gastric and esophageal cancers continue to represent a significant global health burden, with high mortality rates and limited long-term survival for many patients. Esophageal cancer is the 11th most common cancer worldwide with over 510,000 new cases and is the seventh leading cause of cancer mortality, accounting for over 445,000 cancer deaths each year. Patients with esophageal cancer have an overall five-year survival of 22%. Gastric cancer is the fifth most common cancer worldwide with around 968,000 new cases and is also the fifth leading cause of cancer mortality, accounting for approximately 660,000 cancer deaths each year. Patients with gastric cancer have an overall 5-year survival of 38%. PD-1- and PD-L1-targeted immunotherapies, including OPDIVO®, have transformed treatment approaches across multiple cancer types, underscoring the importance of accurate biomarker testing to help identify patients who may benefit from these therapies. PD-L1 IHC 28-8 pharmDx was developed by Agilent in partnership with Bristol Myers Squibb as part of the clinical development program supporting OPDIVO®. Clinical studies CheckMate-648 and CheckMate-649 demonstrated improvements in overall survival and progression-free survival in patients with ESCC, gastric, GEJ, and esophageal adenocarcinoma treated with OPDIVO® and OPDIVO QVANTIG®. PD-L1 IHC 28-8 pharmDx is manufactured by Agilent Technologies, Inc.
お知らせ • Jul 08Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic AnalysisAgilent Technologies Inc. announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production. The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics. Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity. By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, Agilent Technologies Inc. is expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows. Aggregate analysis is a critical quality attribute for a wide range of biotherapeutics, including monoclonal antibodies, antibody-drug conjugates, and emerging modalities. Altura SEC columns build on the success of the Agilent AdvanceBio SEC columns while incorporating Ultra Inert technology to enhance peak shape and aggregate recovery. For aggregate analysis of GLP-1 peptides, Altura SEC columns deliver up to double the sensitivity of inert competitor columns, improving detection of low-level impurities. For liquid chromatography/mass spectrometry (LC/MS) workflows, Altura PLRP-S columns are designed to deliver robust performance under demanding conditions. These capabilities support molecular weight confirmation across protein-based therapeutics and complex biopharmaceutical modalities. The new columns are engineered to deliver faster conditioning, improved peak shape and enhanced sensitivity for challenging analytes. These performance improvements support a broad range of therapeutic modalities, from peptide therapeutics such as GLP-1 to oligonucleotides and large biomolecules including monoclonal antibodies and mRNA. As analytical demands continue to evolve, laboratories require robust and reproducible solutions to support development and quality workflows. Altura columns are part of Agilent's broader portfolio of inert liquid chromatography solutions, designed to provide a fully optimized sample flow path when used in conjunction with Agilent instrumentation and supplies. This integrated approach helps laboratories improve workflow efficiency while maintaining data quality and consistency. The Altura SEC and Altura PLRP-S columns are available globally.
お知らせ • Jul 01Agilent Technologies Launches Xcelligence RTCA Esight AI ModuleAgilent Technologies Inc. announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to gain imaging and impedance insights from the same cells in the same experiment with greater speed and confidence. This streamlined, integrated approach is expected to provide biopharma researchers with a more complete view of cell behavior while reducing variability across users and conditions. Traditional cell segmentation workflows rely on time-consuming and subjective manual setup and analysis steps that increase variability, error and rework, slowing experimental timelines while also requiring a higher level of experimental expertise to achieve consistent results. As biopharma research increasingly demands more complex experiments, higher throughput and greater consistency, integrated workflows are key to efficient scientific progress. AI-driven imaging analysis can help reduce variability across users while decreasing time spent on manual analysis. By replacing subjective, user-influenced thresholding and manual parameter tuning with a one-click approach, the new module delivers standardized analysis across skill levels, experiments and datasets. eSight imaging AI analysis is designed to ensure confident, reliable performance across users, cell types and assay conditions, providing the robustness and accuracy essential for real-world science and users with varying levels of imaging expertise. The new module is expected to reduce time spent on manual analysis, rework and training while supporting broader application of label-free imaging workflows, specifically within drug discovery and in high-throughput biopharma research. By simplifying label-free imaging analysis within an integrated imaging and impedance workflow, eSight AI helps researchers reduce complexity, gain more confident biological insights and accelerate the path from experiment to interpretation.
お知らせ • Jun 26Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP.Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP for approximately $950 million on March 9, 2026. A cash consideration of $950 million will be paid by Agilent Technologies, Inc. As part of consideration, $950 million is paid towards common equity of Biocare Medical, LLC. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group. For the period ending December 31, 2025, Biocare Medical, LLC reported total revenue of $90 million. The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. The deal is expected to be accretive to Agilent’s top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent’s EPS approximately 12 months following close. Barclays Capital Inc. acted as financial advisor for Agilent Technologies, Inc. Sullivan & Cromwell LLP acted as legal advisor for Agilent Technologies, Inc. Joele Frank is serving as strategic communications adviser to Agilent. Jefferies LLC acted as financial advisor for Biocare Medical, LLC. Ropes & Gray LLP acted as legal advisor for Biocare Medical, LLC. Barclays Bank PLC acted as financial advisor for Agilent Technologies, Inc. ICR Healthcare is serving as strategic communications adviser to Biocare. Agilent Technologies, Inc. (NYSE:A) completed the acquisition of Biocare Medical, LLC from an investor group led by Excellere Capital Fund III LP, a fund managed by Excellere Capital Management LLC and GHO Capital Partners LLP on June 25, 2026. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.
Upcoming Dividend • Jun 23Upcoming dividend of US$0.26 per shareEligible shareholders must have bought the stock before 30 June 2026. Payment date: 22 July 2026. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (0.9%).
Recent Insider Transactions • Jun 06Independent Director recently sold €186k worth of stockOn the 29th of May, G. Dolsten sold around 2k shares on-market at roughly €116 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €922k more than they bought in the last 12 months.